Cannara Biotech Dividend

Dividend criteria checks 0/6

Cannara Biotech does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	CA$0.10
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LOVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LOVE's dividend payments have been increasing.

Dividend Yield vs Market

Cannara Biotech Dividend Yield vs Market

How does LOVE dividend yield compare to the market?
Segment	Dividend Yield
Company (LOVE)	n/a
Market Bottom 25% (CA)	1.9%
Market Top 25% (CA)	6.5%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast in 3 Years (LOVE)	n/a

Notable Dividend: Unable to evaluate LOVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LOVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LOVE's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LOVE has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Cannara Biotech Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)

Independent Director recently bought CA$60k worth of stock

Investor sentiment improves as stock rises 24%

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)

Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark

Independent Director recently bought CA$81k worth of stock

Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Cannara Biotech Inc. Announces New Products Launch

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cannara Biotech Inc. Receives Processing and Cultivation License

Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in Quebec

Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)

Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.

Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Full year 2020 earnings released: CA$0.017 loss per share

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021

Cannara Biotech Inc. Appoints Donald Olds to Board of Directors

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies